Impact of tranexamic acid use in total hip replacement patients: A systematic review and meta-analysis
Article History
-
Received: ,
Accepted: ,
Abstract
Abstract
Tranexamic acid (TXA) dose in the context of primary complete hip replacements (THA) is still a hot debate about the best way to administer TXA. The need to select the most efficient and secure TXA dosing regimen, taking into account elements like perioperative bleeding, postoperative complications, and patient outcomes, has been emphasized by numerous studies. Improving clinical procedures and the general efficacy and safety of employing TXA in THA surgeries requires addressing this ongoing debate.
For this systematic review, We looked at the safety and efficacy of administering TXA intravenously (iTXA) and topically (tTXA) during THA. A thorough search turned up ten randomized controlled trials with 1295 individuals. Parameters evaluated included blood loss, Hb level on the day following surgery, transfusion rates, and drainage volume.
Strategies had comparable impacts on deep vein thrombosis occurrences and wound complications. iTXA produced considerably less intraoperative blood loss (WMD = −12.687), concealed blood loss (WMD = 14.276), and the greatest hemoglobin drop (WMD = −0.400) when compared to tTXA.
Both administration techniques were secure and efficient in primary THA, although iTXA showed superior results in lowering blood loss and Hb decline.
Keywords
This article was originally published by Reed Elsevier India Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
1 Introduction
Currently, the most effective surgical procedure for treating severe hip joint diseases is total hip arthroplasty (THA), such as inflammatory or degenerative arthritis, misplaced femoral neck fractures, and end-stage avascular necrosis of the femur head.1,2 Globally, more than 500,000 THA procedures are carried out each year, and this number is progressively rising as more and more participants age.3,4 On the other hand, anemia that results from postoperative blood loss is a frequent and harmful side effect of joint replacement surgery—increasing hazards overall, especially for senior patients.5 Both autologous and allogeneic blood transfusions effectively replace lost blood, but the former has a finite supply and declines with age, while the latter has negative effects such as infection, viral transmission, allergic reactions, and higher mortality rates.6,8 To lessen the need for transfusions during major orthopedic procedures, TXA has been frequently used, and studies7,9–11 have demonstrated that it is both amazingly effective and safe.
Theoretically, intravenous injection of TXA may pose a risk of thrombotic events as it is an antifibrinolytic drug. Pulmonary embolism and deep vein thrombosis (DVT) are at increased risk, for example. Alternative “safer” TXA administration methods, such as topical application and oral administration, have therefore arisen. Recent research indicates no appreciable differences in thrombus risk or bleeding control between these methods..12,13 Due to their representativeness in terms of effectiveness and safety, intravenous and local delivery of TXA are frequently contrasted among these methods.14–17 In total joint arthroplasty, intravenous tranexamic acid (ivTXA) demonstrated comparable transfusion needs and safety as topical tranexamic acid (tTXA) while demonstrating a reduced maximal hemoglobin (Hb) decline. This was the conclusion of a 2014 meta-analysis..14 An RCT, or randomized controlled study, was recently conducted, although it was found in 2019 that local administration had a higher therapeutic value compared to intravenous TXA at the same dosage in THA.18–20 The TXA administration method in THA is still debatable. An examination of the efficiency and security of local and injection TXA injections during THA was conducted.
2 Materials and methods
The study design followed PRISMA CRD42023445597 standards.
2.1 Literature search
We conducted a thorough literature search using online databases like Google Scholar, PubMed, Embase, and Cochrane Library: Finding RCTs comparing TXA treatments in the THA. with full-text publications available in English. Up until June 2023, the investigation was ongoing. The search strategy made use of the Boolean operators “tranexamic acids and TXA,” “intravenous and close (ivTXA) and intra-articular and topical,” and “THA and total hip arthroplasty."
2.2 Criteria for inclusion and exclusion
Include RCTs comparing IV vs. local/intra-articular TXA in THA, reporting on TXA safety and efficacy across various modalities.
Studies that didn't meet the inclusion criteria or had poor quality were excluded. Patient age, monitoring duration, or preoperative condition were not taken into account to offer a full evaluation.
2.3 Extract metadata
Two unbiased reviewers independently extracted each piece of data, with the help of a third author when necessary. Author, nation, calendar year, sample size, average age, gender distribution, TXA intervention dosage and method of administration, preoperative hemoglobin level, general surgery data, and results were all extracted from the data. The main objectives were transfusion rates, hemoglobin concentrations, comprising surgical day one and maximal hemoglobin decline, Blood loss during surgery (IBL), hidden blood loss (HBL), and total blood loss (TBL), which were the three blood loss metrics used. Secondary goals included the amount of drain and difficulties such as wounds, DVT, and length of hospital stay (LOS).
Using instruments from the Cochrane Collaboration, we evaluated randomized controlled trials' level of quality.20,21 The following important bias risk variables were listed in a “risk of bias” table: randomization, sources that use blinding, insufficient data, selective reporting, etc. reviewed impartially (high, unclear, or low bias) by three raters. Another key author was brought in when there was a disagreement to negotiate a resolution.
2.4 Analytical statistics
was done with Stata 11.0 (USA, TX, Stata Corp. LP) on the retrieved data. Data were deemed to have considerable heterogeneity when significant heterogeneity was indicated by an I2 > 50 % and a p < 0.1. based on Cochran's Q statistic, and a random-effects model combined with the I2 statistic was utilized for conducting meta-analysis. In the remaining circumstances, a fixed-effects model was employed. with 95 % confidence intervals, relative risks for binary outcomes were reported. Blood loss was one of many continuous outcomes that were presented. Using 95 % confidence intervals as standardized mean differences or weighted mean differences It was calculated to determine hemoglobin levels, LOS WMD with 95 % CIs, and drainage volume. The criterion of statistical significance for identifying differences had a 0.05 p-value.
2.5 Search results
(Fig. 1). Initially, 456 articles were discovered in the selected datasets. Firstly, 314 records were excluded due to duplication or irrelevance. Subsequently, we screened the titles and abstracts and excluded 96 reports based on eligibility criteria. The remaining 46 articles were read in full, and 36 reports were excluded due to insufficient data. Finally, data extraction and meta-analysis were performed on ten randomized controlled studies that matched the requirements for inclusion (Table 1).

2.6 Learning characteristics
A total of 10 randomized controlled studies evaluating the effects of tranexamic acid (TXA) administered intravenously (IV) versus locally (local) in individuals undergoing complete hip replacement (THA) were included in this investigation. These trials were published between 2014 and 2020. 1295 patients participated in total, with 656 receiving IV therapy and 639 receiving topical therapy. displays demographic information, including average age, gender distribution, and BMI. The administration of TXA, transfusion standards, and the avoidance of DVT events during THA were all covered in great detail in each experiment. One RCT examined the dynamics of coagulation when TXA was administered. provides more surgical details (Table 2).
| Study | Year | Nation | Recruitment | Sample Mean age (Y) | Gender (M/F) | BMI | Preoperative Hb (g/dl) | ||||||
| ivTXA | tTXA | ivTXA | tTXA | ivTXA | tTXA | ivTXA | tTXA | ivTXA | tTXA | ||||
| Wei et al.26 | 2014 | China | 2013–2014 | 101 | 102 | 63.6 ± 7.0 | 60.2 ± 6.5 | 39/62 | 35/67 | 24.2 ± 3.1 | 25.3 ± 3.0 | – | – |
| North et al.28 | 2015 | USA | 2013–2013 | 70 | 69 | 64.1 ± 12.0 | 65.7 ± 10.6 | 38/32 | 39/30 | 31.1 ± 5.4 | 31.1 ± 6.4 | 13.4 ± 1.3 | 13.2 ± 1.4 |
| Zhang et al.29 | 2016 | China | 2013–2014 | 25 | 25 | 44.5 ± 2.4 | 44.3 ± 3.7 | 14/11 | 13/12 | 24.3 ± 3.2 | 23.5 ± 3.4 | 126.5 ± 6.5 | 13.02 ± 0. 58 |
| Xie et al.14 | 2016 | China | 2014–2015 | 70 | 70 | 59.53 ± 11.50 | 62.24 ± 11.04 | 20/50 | 25/45 | 24.16 ± 3.08 | 24.47 ± 3.30 | 13.32 ± 1.26 | 13.22 ± 0.84 |
| Luo et al.9 | 2017 | China | 2016–2017 | 60 | 60 | 59.53 ± 11.50 | 62.24 ± 11.04 | 27/33 | 25/35 | 24.5 ± 3.87 | 25.27 ± 4.19 | 13.71 ± 0.75 | 14.07 ± 0.99 |
| Zhou et al.30 | 2018 | China | 2014–2015 | 57 | 56 | 63.2 ± 10.0 | 65.8 ± 9.4 | 12/45 | 17/39 | 23.7 ± 3.2 | 23.2 ± 3.1 | 12.74 ± 1.4 | 12.96 ± 1.28 |
| Xu et al.12 | 2019 | China | 2016–2018 | 68 | 72 | 62.5 ± 6.6 | 61.9 ± 6.1 | 32/36 | 34/38 | 22.0 ± 2.3 | 22.3 ± 2.7 | – | – |
| Vles et al.33 | 2020 | Belgium | 2014–2015 | 60 | 60 | 61.5 ± 11.8 | 64.0 ± 13.4 | 29/31 | 22/38 | 27.6 ± 4.4 | 26.3 ± 4.4 | 14.5 ± 1.23 | 13.9 ± 1.5 |
| Gómez-Aparicio et al.5 | 2020 | Spain | 2017–2019 | 110 | 85 | 63.94 ± 10.80 | 65.52 ± 10.92 | 48/62 | 45/40 | 28.43 ± 3.81 | 29.20 ± 5.26 | 14.21 ± 1.31 | 14.30 ± 2.21 |
| Zhang et al.18 | 2020 | China | 2018–2019 | 36 | 36 | 66.98 ± 9.01 | 67.98 ± 8.87 | 15/21 | 16/20 | 23.4 ± 2.01 | 23.86 ± 2.38 | – | – |
| Study | Year | Nation | Recruitment | Sample Mean Age (Y) | Gender (M/F) | BMI (ivTXA/tTXA) | Preoperative Hb (g/dl) (ivTXA/tTXA) |
| Wei et al.26 | 2014 | China | 2013–2014 | 101 | 63.6 ± 7.0 | 39/62 | 24.2 ± 3.1/25.3 ± 3.0 |
| North et al.28 | 2015 | USA | 2013–2013 | 70 | 64.1 ± 12.0 | 38/32 | 31.1 ± 5.4/31.1 ± 6.4 |
| Zhang et al.29 | 2016 | China | 2013–2014 | 25 | 44.5 ± 2.4 | 14/11 | 24.3 ± 3.2/23.5 ± 3.4 |
| Xie et al.14 | 2016 | China | 2014–2015 | 70 | 59.53 ± 11.50 | 20/50 | 24.16 ± 3.08/24.47 ± 3.30 |
| Luo et al.9 | 2017 | China | 2016–2017 | 60 | 59.53 ± 11.50 | 27/33 | 24.5 ± 3.87/25.27 ± 4.19 |
| Zhou et al.30 | 2018 | China | 2014–2015 | 57 | 63.2 ± 10.0 | 12/45 | 23.7 ± 3.2/23.2 ± 3.1 |
| Xu et al.12 | 2019 | China | 2016–2018 | 68 | 62.5 ± 6.6 | 32/36 | 22.0 ± 2.3/22.3 ± 2.7 |
| Vles et al.33 | 2020 | Belgium | 2014–2015 | 60 | 61.5 ± 11.8 | 29/31 | 27.6 ± 4.4/26.3 ± 4.4 |
| Gómez-Aparicio et al.5 | 2020 | Spain | 2017–2019 | 110 | 63.94 ± 10.80 | 48/62 | 28.43 ± 3.81/29.20 ± 5.26 |
| Zhang et al.18 | 2020 | China | 2018–2019 | 36 | 66.98 ± 9.01 | 15/21 | 23.4 ± 2.01/23.86 ± 2.38 |
| study (year) | Surgical approach | Anesthesia | ivTXA | tTXA | Drainage | Transfusion criteria | VTE prophylaxis | Follow-up |
| Wei et al. (2014)26 | Posterolateral approach | NA | 1 dose: 3.0 g pre-incision. | 3.0 g are diluted in 100 ml.20 ml acetabulum, 20 ml femoral, and 60 ml post-closure irrigation. | Clamped for 2 h Removed on the 24 h postoperative | Hb < 90 g/l | LMWH | 3 months |
| North et al. (2015)25 | NA | NA | 1 g/50 ml pre-incision is the initial dose.Pre-closure: 1.0 g/50 ml, second dose. | Before closure: 2.0 g/100 ml irrigation. | No drains | Hb < 70 g/l or <80 g/l with anemic complications | LMWH for 21 days rivaroxaban for 35 days or aspirin for 21 days | NA |
| Zhang et al. (2016)29 | A front-side approach | Spinal or general anesthesia | 1.0 g/250 ml pre-procedure is one dose. | After closure, inject 1 g per 100 ml. | Clamped for 3 hRemoved on the 45h postoperative | Hb < 70 g/l or >80 g/l with anemic complications | LMWH for 2 weeks | 1 year |
| Xie et al. (2016)14 | Posterolateral approach | General anesthesia | 1.5 g pre-incision (15 min) each dosage. | 3.0 g/150 ml for dilution.Acetabulum, femoral, and post-closure irrigation volumes total 50 ml. | Clamped for 30 minRemoved on the 24 h postoperative | Hb < 70 g/l or >70 g/l with anemic complications | LMWH until discharge Rivaroxaban for another 30 days | 3 months |
| Luo et al. (2017)9 | Posterolateral approach | General anesthesia | 1 dose: 20 mg/kg pre-incision (5 min). | Dilution: 2.0 g/150 ml.Irrigation: 50 ml acetabulum, 50 ml femoral, 50 ml post-closure. | No drains | Hb < 70 g/l or >70 g/l with anemic complications | LMWH until dischargeRivaroxaban for another 15 days | 3 months |
| Zhou et al. (2018)30 | Anterolateral approach | General anesthesia | 1st dose: 10 mg/kg pre-incision2nd dose: 10 mg/kg post 3 h | 3.0 g/60 ml irrigation 3 min before closing | A 2-h stampede removed 48 h after surgery | Hb < 80 g/l or <100 g/l with anemic complications | Rivaroxaban for 15 days | 6 weeks |
| Xu et al. (2019)12 | Posterolateral approach | Spinal anesthesia | 1 dose: 20 mg/kg, 5 min before incision. | Irrigated at 2.0 g/50 ml before closure | Clamped for 2 hRemoved on the 48h postoperative | (Hb) level <70 g/l or >70 g/with anemic complications | Rivaroxaban for 35 days | 6 months |
| Vles et al. (2020)33 | Direct anterior approach | Spinal anesthesia | 1.5 g/100 ml, one dosage, just before closure. | 3.0 g/100 ml injected after closure | Clamped for 2 h | Hb < 80 g/l or <85 g/l with anemic complications | LMWH until dischargeRivaroxaban for another 30 days | NA |
| Gómez-Aparicio et al. (2020)5 | NA | NA | 15 mg/kg once, 15–20 min prior to incision. | 2.0 g/100 ml injected after closure | Clamped for 2 hRemoved on the 48h postoperative | Hb < 80 g/l or <100 g/l with anemic complications | LMWH for 30 days | NA |
| Zhang et al. (2020)18 | Posterolateral approach | General anesthesia | 2.0 g/100 ml, 1 dosage, 30 min before incision. | Injection of 2.0 g/100 ml upon closure | Clamped for 2 hRemoved on the 24 h postoperative | Hb < 70 g/l or <70 g/l with anemic complications | LMWH until dischargeRivaroxaban for another 10 days | NA |
2.7 Risk bias
Two independent reviewers assessed the bias risk. Six studies reported creating random sequences. Low danger of bias was present in participant and staff blinding and allocation concealment in five studies. A low risk of bias was revealed by six studies in outcome assessment blinding. indicated no evidence of selective reporting in all ten RCTs (Table 3).
| Study (year) | Sequence generation | Allocation concealment | Blinding of outcome assessors | Incomplete outcome data | Selective outcome reporting | Others |
| Wei et al. (2014)26 | Low | Low | Low | Low | Low | Low |
| North et al. (2015)28 | Unclear | Unclear | Low | Low | Low | Low |
| Zhang et al. (2016)29 | Low | Low | Unclear | Low | Low | Low |
| Xie et al. (2016)14 | Unclear | Low | Low | Low | Low | Low |
| Luo et al. (2017)9 | Low | Unclear | High | Low | Low | Low |
| Zhou et al. (2018)30 | Low | Low | Low | Low | Low | Low |
| Xu et al. (2019)12 | Low | Low | High | Low | Low | Unclear |
| Vles et al. (2020)33 | Low | Unclear | Low | Low | Low | Low |
| Gómez-Aparicio et al. (2020)5 | High | Unclear | Low | Low | Low | Unclear |
| Zhang et al. (2020)18 | High | Unclear | High | Low | Low | Unclear |
3 Results from the meta-analysis
Using markers such as TBL, IBL, and HBL, the study contrasted the application of IV and topical TXA during THA, postoperative day 1 Hb level, maximal Hb decline, transfusion prevalence, draining quantity, wound problems, DVT occurrences, and LOS.
3.1 Losing blood
Total hip arthroplasty (THA) subgroup studies based on different types of blood loss, including overall, intraoperative, and covert bleeding, were performed to thoroughly compare blood loss among intravenous (IV) and topical applications of TXA. Seven randomized controlled trials (RCTs) including 1050 individuals were used to gather data on total blood loss; the IV group had 536 cases, while the topical group included 514 cases. The data showed no observable heterogeneity (p = 0.306; I2 = 16.2 %) Fig. 2. As shown in9,26–28,30,32,34 The groups receiving topical and intravenous TXA did not significantly vary in the total volume of blood loss during THA. (p = 0.073; CI: 85.153- 3.823; WMD = −40.665). Four relevant studies on intraoperative blood loss (I2 = 0.0; p = 0.763 %) were found without statistical heterogeneity, and a comparison of the two groups showed statistically significant differences. P = 0.010 (Fig. 3)29,30,32,33 (WMD = 12.687; CI: 22.291–3.083). More than topical administration, intravenous (IV) TXA administration decreased intraoperative blood loss during THA, according to the current meta-analysis.


Modeling random effects had to be used for analysis since the three trials (IV 216 and topical 191) on concealed blood loss revealed substantial variation among the RCTs (I2 = 20.6 %; p = 0.284). The results showed statistically noteworthy variations in covert blood loss among both subgroups (p < 0.001). CI: 9.936–19.459; WMD = 14.276. The findings demonstrated that IV injections of TXA caused less unreported blood loss during THA than topical therapy.
Overall, this meta-analysis indicates that IV TXA administration is related to reduced intraoperative and hidden blood loss during THA when compared to topical administration.
3.2 Hb level
A combined analysis revealed no difference in postoperative day 1 Hb that was statistically significant (p = 0.308; WMD = −1.803; CI: 5.269 -1.663). Maximum Hb decline during THA was considerably reduced with ivTXA (p < 0.001) (CI: 0.577-0.222; WMD = −0.400) (Fig. 4).9,27,28,30 The model was random-effects. Major heterogeneity was found (p < 0.1; I2 > 50 %)

3.3 Rate transfusion
Blood transfusion rates were reported in all 10 RCTs. 9.9 % (63/639) of the topical group required transfusions. 12.0 % of the IV group (79/656). There is no discernible heterogeneity (I2 = 0 %; p = 0.442). The observed results did not reach statistical significance9,18,26–28,30,32–34,36 (Fig. 5; OR: 1.274; CI: 0.885–1.835; p = 0.193).

Data from eight studies (1043 patients) using a single intravenous dosage of TXA and eight investigations, with 1247 participants using a topical dose of less than 2 g, were included in the subgroup analysis. Because there was little heterogeneity (I2 = 50 %; p > 0.1), it was modeled with a fixed effect. Between topical (2 g) and intravenous methods, there was no discernible difference in transfusion rates. according to the study(OR:1.257; p = 0.222; 95 % CI: 0.870, 1.815). Similar to the topical method, the single intravenous dose of TXA did not significantly alter transfusion rates (Fig. 6) (OR = 1.504, 95 % CI: 0.942–2.401; p = 0.088)..9,26,27,29,32,33

3.4 Drain capacity
568 individuals in 4 studies had drain capacity reported. Given the substantial heterogeneity, it made use of a random-effects model. (p < 0.001; I2 = 96.3 %). There was no discernible difference in the two groups' drainage volumes. 44.152, 95 % WMD p = 0.500; CI: 84.118, −172.422 (Table 4).
| Results | Studies numbers | Groups size | Overall effect | Heterogeneity | ||||
| ivTXA | tTXA | Effect estimate | 95 % CI | p-value | I2(%) | p-value | ||
| Transfusion rate | 10 | 656 | 639 | OR, 1.274 | 0.885, 1.835 | 0.193 | 0.0 % | 0.442 |
| 2. g of tTXA | 9 | 632 | 615 | OR, 1.257 | 0.870, 1.815 | 0.222 | 7.3 % | 0.374 |
| one ivTXA dosage | 8 | 529 | 514 | OR, 1.504 | 0.942, 2.401 | 0.088 | 0.0 % | 0.483 |
| Total loss blood | 7 | 536 | 514 | WMD, −40.665 | −85.153, 3.823 | 0.073 | 16.2 % | 0.306 |
| perioperative bleeding | 4 | 210 | 213 | WMD, −12.687 | −22.291, −3.083 | 0.010 | 0.0 % | 0.763 |
| Unreported blood loss | 3 | 216 | 191 | WMD, 14.276 | 9.936, 19.459 | <0.001 | 20.6 % | 0.284 |
| 1st Hb after surgery | 6 | 346 | 321 | WMD, −1.803 | −5.269, 1.663 | 0.308 | 74.3 % | 0.002 |
| Drainage capacity | 4 | 295 | 273 | WMD, 44.152 | −84.118, 172.422 | 0.500 | 96.3 % | 0.000 |
| Maximum drop Hb | 4 | 257 | 255 | WMD, −0.400 | −0.577, −0.222 | <0.001 | 11.4 % | 0.336 |
| DVT | 9 | 545 | 549 | RD, 0.000 | −0.014, 0.014 | 0.992 | 0.0 % | 0.906 |
| Infection complications | 5 | 409 | 389 | RD, −0.003 | −0.028, 0.022 | 0.816 | 0.0 % | 0.920 |
| Duration of stay | 6 | 437 | 413 | WMD, 0.283 | −0.152, 0.718 | 0.202 | 88.0 % | 0.000 |
3.5 Complications
There was no discernible heterogeneity among the nine articles that included data on DVT events following THA (I2 = 0.0 %; p = 0.906). No discernible difference in DVT was seen between 545 patients receiving ivTXA and 549 getting tTXA during THA (RD = 0.000; p = 0.992; 95 % CI: 0.014-0.014) (Fig. 7)..9,26–30,32,33 Five studies presented data on wound complications without statistically significant heterogeneity. There was no noticeable distinction between the two sets of people. (p = 0.816, I2 = 0 %, 95 % CI: 0.028–0.022; OR: 0.003).

3.6 Duration of stay
We investigated using a random-effects model LOS data from six studies (850 patients) resulting from substantial heterogeneity (I2 = 88.0 %; p = 0.000). There was no proof of a meaningful difference. (OR: 0.283; p = 0.202; 95 % CI: 0.152-0.718).
4 Discussion
Improved postoperative recovery depends on proper perioperative blood control.22 Tranexamic acid, an antifibrinolytic, decreases post-total joint arthroplasty blood loss and transfusion rates. TXA is frequently administered via a variety of methods (oral, intravenous, topical, and combination).12,13,22,23 Topical (tTXA) and intravenous (ivTXA) techniques are the main topics of discussion. There were no discernible statistical variations between the routes, according to earlier meta-analyses. ivTXA versus tTXA during THA is evaluated for effectiveness and safety in this comprehensive meta-analysis and systematic review. it is addressing the paucity of research in this particular area.12,17,19,20,24 It includes 10 randomized controlled trials (RCTs). It seeks to reduce heterogeneity brought on by various surgical techniques used in total knee arthroplasty (TKA) and THA.18,25–34
In this study, we looked at THA-related data on blood loss. The ivTXA group's average TBL was, however, lower than the tTXA group's. Overall blood loss (TBL) did not differ statistically substantially between the routes. Similar to how topical TXA caused significantly more intraoperative blood loss (IBL), ivTXA caused much less IBL. Additionally, in line with earlier data,14 ivTXA showed much less hidden blood loss (HBL), which was around 50 % of TBL.
The Hb level is essential for determining whether a postoperative transfusion is necessary. After surgery, the two groups' postoperative day 1 hemoglobin levels did not differ statistically significantly, the ivTXA group saw a reduced maximum Hb drop caused by HBL around postoperative days 3–4. The advantage of a reduced maximal Hb drop brought on by intravenous TXA may haveten the recovery of older THA patients.
The intravenous dose is ≥ 2 g. Despite intravenous administration of TXA (ivTXA) showing greater success in reducing intraoperative blood loss (IBL), postoperative blood loss (HBL), and maximum hemoglobin drop compared to topical TXA (tTXA), the transfusion rates between ivTXA and tTXA groups were comparable. This may be attributed to the randomized controlled trials included using different TXA dosages, with similar total blood loss (TBL). In subgroup analysis, a single intravenous dose of ivTXA (≥2 g) did not demonstrate a difference in reducing transfusion rates compared to tTXA.35–39 This could be because, during total hip arthroplasty (THA), tTXA achieves effective local microvascular hemostasis by reducing fibrinolysis at surgical bleeding sites, while a single intravenous dose of ivTXA improves coagulation function compared to tTXA.35,36 It is noteworthy that earlier meta-analyses13,14,22,24 found similar impacts on transfusion rates for both methods during THA or total knee arthroplasty (TKA).
After THA, water volume was comparable between the two pathways. Routine postoperative anticoagulation measures and differentiated anticoagulation management may have lessened the actual differences in thrombotic events between the two TXA routes, even if tTXA may affect drainage volume due to residual TXA dilution in the joint fluid.
Wound infection is a concern after surgery. However, there was little variation in wound complications observed between the intravenous and tTXA groups. Reports of topical TXA increasing wound tension and complications are more common in knee joints than hip joints, likely due to different anatomical conditions.36
Two of the many benefits of this study include the inclusion of only RCTs for higher reliability and the thorough analysis of the most relevant RCTs comparing topical and intravenous TXA in THA. However, there are several disadvantages, including significant heterogeneity between studies caused by differences in intraoperative leadership, methodological problems in some trials, and a lack of data that affects quality evaluation. Postoperative issues may also be overstated if there is insufficient long-term follow-up data.
5 Conclusion
The comparison between intravenous TXA and topical TXA in total hip arthroplasty (THA) shows similar effects on wound complications, drainage volume, postoperative hemoglobin levels, transfusion rate, and total blood loss. However, there are differences in hidden blood loss and intraoperative bleeding.
Funding
Not applicable’ for that section.
Ethics approval
The registration number for PROSPERO (the International Prospective Register of Systematic Reviews) is CRD42023445597.
Consent to participate
This study involved the collection of no patient-identifiable data. There was only anonymous data gathered. Before collecting anonymous data, prior authorization from the Deputy Data Protection Officer was secured. The Research Ethics Committee of China Medical University Hospital deemed this study to be a low-risk retrospective chart review, so the participants' express agreement was not necessary.
Consent for publication
For that section, it is not applicable.
Contributions
HW: Writing: first draft; and Writing: editing and review.
SD: supervision; validation; visualization; roles.
Entanglements in interest
The writers say they have no conflicting agendas.
Permission to publicate
For that section, not applicable.
Data accessibility
The authors might seek access to the datasets created for this study.
Data availability
The datasets generated for this study are available upon request to the authors.
References
- Does surgeon volume affect outcomes following primary total hip arthroplasty? A systematic review. J Arthroplasty. 2018;33(10):3329-3342.
- [Google Scholar]
- Trends in total hip arthroplasty in Germany from 2007 to 2016: what has changed and where are we now? Z für Orthop Unfallchirurgie. 2021;159(2):173-180.
- [Google Scholar]
- Rates of total joint replacement in the United States: future projections to 2020–2040 using the national inpatient sample. J Rheumatol. 2019;46(9):1134-1140.
- [Google Scholar]
- Guidelines for perioperative care in elective colorectal surgery: enhanced Recovery after Surgery (ERAS®) Society recommendations: 2018. World J Surg. 2019;43:659-695.
- [Google Scholar]
- The role of intra‐operative cell salvage in patient blood management for revision hip arthroplasty: a prospective cohort study. Anaesthesia. 2020;75(4):479-486.
- [Google Scholar]
- Meta-analysis of the association between preoperative anaemia and mortality after surgery. Journal of British Surgery. 2015;102(11):1314-1324.
- [Google Scholar]
- Allogeneic blood transfusion is a significant risk factor for surgical-site infection following total hip and knee arthroplasty: a meta-analysis. J Arthroplasty. 2017;32(1):320-325.
- [Google Scholar]
- Cost-benefit analysis of the use of tranexamic acid in total replacement hip surgery. J Clin Anesth. 2019;57:124-128.
- [Google Scholar]
- The safety of tranexamic acid in total joint arthroplasty: a direct meta-analysis. J Arthroplasty. 2018;33(10):3070-3082. e3071.
- [Google Scholar]
- The current place of tranexamic acid in the management of bleeding. Anaesthesia. 2015;70:50.
- [Google Scholar]
- The safest and most efficacious route of tranexamic acid administration in total joint arthroplasty: a systematic review and network meta-analysis. Thromb Res. 2019;176:61-66.
- [Google Scholar]
- Comparison of intravenous, topical or combined routes of tranexamic acid administration in patients undergoing total knee and hip arthroplasty: a meta-analysis of randomised controlled trials. BMJ Open. 2019;9(1)
- [Google Scholar]
- Comparison of intravenous versus topical tranexamic acid in primary total hip and knee arthroplasty: an updated meta-analysis. Thromb Res. 2017;153:28-36.
- [Google Scholar]
- Intravenous versus topical tranexamic acid in primary total hip replacement: a meta-analysis. Medicine. 2016;95(50)
- [Google Scholar]
- Comparison of efficacy and safety of topical versus intravenous tranexamic acid in total hip arthroplasty: a meta-analysis. Medicine. 2016;95(36)
- [Google Scholar]
- Intravenous versus topical tranexamic acid in primary total hip replacement: a systemic review and meta-analysis. Int J Surg. 2016;32:10-18.
- [Google Scholar]
- Better treatment values in local application of tranexamic acid (TXA) than intravenous application with the same dose in total hip arthroplasty. Adv Ther. 2020;37:4346-4355.
- [Google Scholar]
- Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:103-112.
- [Google Scholar]
- Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1-9.
- [Google Scholar]
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Br Med J. 2011;343
- [Google Scholar]
- Beyond surgery: clinical and economic impact of Enhanced Recovery after Surgery programs. BMC Health Serv Res. 2018;18:1-4.
- [Google Scholar]
- The safety of tranexamic acid in total joint arthroplasty: a direct meta-analysis. J Arthroplasty. 2018;33(10):3070-3082. e3071.
- [Google Scholar]
- A systematic review and meta-analysis of the topical administration of tranexamic acid in total hip and knee replacement. The bone & joint journal. 2014;96(8):1005-1015.
- [Google Scholar]
- Effect of tourniquet use on activation of coagulation in total knee replacement. Clin Orthop Relat Res. 2000;371:169-177.
- [Google Scholar]
- Comparison of topical and intravenous tranexamic acid on blood loss and transfusion rates in total hip arthroplasty. J Arthroplasty. 2014;29(11):2113-2116.
- [Google Scholar]
- Combined use of intravenous and topical tranexamic acid following cementless total hip arthroplasty: a randomised clinical trial. Hip Int. 2016;26(1):36-42.
- [Google Scholar]
- Topical vs intravenous tranexamic acid in primary total hip arthroplasty: a double-blind, randomized controlled trial. J Arthroplasty. 2016;31(5):1022-1026.
- [Google Scholar]
- What is the optimal approach for tranexamic acid application in patients with unilateral total hip arthroplasty? Orthopä. 2016;45(7):616-621.
- [Google Scholar]
- Is topical or intravenous tranexamic acid preferred in total hip arthroplasty? A randomized, controlled, noninferiority clinical trial. PLoS One. 2018;13(10)
- [Google Scholar]
- Which route of administration of acid tranexamic, intravenous or intra-articular, is more effective in the control of post-surgical bleeding after a total hip arthroplasty? A prospective, controlled and randomized study. Rev Española Cirugía Ortopédica Traumatol. 2019;63(2):138-145.
- [Google Scholar]
- Application of thromboelastography to evaluate the effect of different routes administration of tranexamic acid on coagulation function in total hip arthroplasty. J Orthop Surg Res. 2019;14:1-8.
- [Google Scholar]
- Hidden blood loss in direct anterior total hip arthroplasty: a prospective, double blind, randomized controlled trial on topical versus intravenous tranexamic acid. Musculoskeletal Surgery. 2021;105:267-273.
- [Google Scholar]
- Results after the application of tranexamic acid intravenous or intra-articular in the control of postsurgical bleeding after total hip arthroplasty: a randomized controlled trial. Eur J Orthop Surg Traumatol. 2020;30:1221-1230.
- [Google Scholar]
- Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement. Br J Anaesth. 2003;90(5):596-599.
- [Google Scholar]
- Changes of hemoglobin and hematocrit in elderly patients receiving lower joint arthroplasty without allogeneic blood transfusion. Chin Med J. 2015;128(1):75-78.
- [Google Scholar]
- Tranexamic acid in patients undergoing noncardiac surgery. N Engl J Med. 2022;386(21):1986-1997.
- [Google Scholar]
- Hypotension-avoidance versus hypertension-avoidance strategies in noncardiac surgery: an international randomized controlled trial. Ann Intern Med. 2023;176(5):605-614.
- [Google Scholar]
- Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery. Trials. 2022;23(1):101.
- [Google Scholar]

